Itulazax

Betula verrucosa, the active ingredient in Itulazax, is a allergen extract (sublingual immunotherapy) presented as a sublingual formulation for sublingual use. It is indicated for the treatment of allergic rhinitis and seasonal allergic rhinoconjunctivitis caused by birch (Betula) pollen in patients with confirmed sensitivity.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution.

Itulazax is employed in allergy immunotherapy to modify the immune response to birch pollen.

- Allergic rhinitis caused by birch pollen: reduces nasal congestion, sneezing, itching and watery discharge. - Seasonal allergic rhinoconjunctivitis due to Betula verrucosa: improves ocular symptoms and overall quality of life. - Birch pollen‑induced allergic conjunctivitis: lessens eye redness, itching and tearing.

Sublingual exposure to Betula verrucosa extract may be associated with local and systemic reactions.

Common Side Effects: - Oral itching or mild irritation. - Throat discomfort or mild swelling. - Transient taste disturbance. - Mild headache. - Minor gastrointestinal upset. - Localized erythema at the administration site.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Angioedema involving the face or airway. - Bronchospasm or severe respiratory distress. - Eosinophilic esophagitis. - Severe urticaria.

Before prescribing Itulazax, clinicians should consider several precautionary measures.

- Confirm diagnosis: verify birch pollen sensitivity through skin testing or specific IgE. - Monitor initial doses: observe patients for at least 30 minutes after the first administration. - Asthma status: avoid use in patients with uncontrolled or severe asthma. - Concomitant allergen therapy: do not combine with other allergen immunotherapies without specialist guidance. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Itulazax may interact with certain medications; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of anaphylaxis. - ACE inhibitors: increase risk of angioedema. - Concurrent sublingual immunotherapy with different allergens: heightened systemic reaction risk.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce local side‑effects but do not eliminate systemic risk. - Systemic corticosteroids: could blunt the immunologic response. - Immunosuppressants: may diminish treatment efficacy.